Sign inJoin waitlistJoin the waitlist

Thomas Karasic

Assistant Professor, Medicine · University of Pennsylvania Health System

Credentials: · ·

History

University of Pennsylvania Health System
Present
University of Pennsylvania Health System
Present

Hematology and Medical Oncology
University of Pennsylvania
2015–2018
Internal Medicine
2012–2015
Columbia Univ Coll of Phys & Surgeons
2008–2012

Research

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
New England Journal of Medicine · 2023 · 502 citations
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial
JAMA Oncology · 2019 · First of 14 authors · 261 citations
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
Journal of Clinical Oncology · 2021 · 214 citations

Peter O'Dwyer
11 papers
Mark O'Hara
10 papers
Ursina Teitelbaum
10 papers
Kim Reiss-Binder
9 papers
Charles Schneider
7 papers
TB
Timothy Brown
7 papers
Edgar Ben-Josef
5 papers
Jennifer Eads
4 papers
Lipika Goyal
4 papers
Nevena Damjanov
4 papers · 2 as a fellow
Robert Vonderheide
4 papers
Emma Furth
3 papers

Clinical trials

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)
Principal investigator · Withdrawn · Phase 1
Abramson Cancer Center at Penn Medicine
2024–2028
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Principal investigator · Withdrawn · Phase 2
Abramson Cancer Center at Penn Medicine
2020–2022
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Principal investigator · Terminated · Phase 2
Abramson Cancer Center at Penn Medicine
2019–2022
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Principal investigator · Terminated · Phase 2
Abramson Cancer Center at Penn Medicine
2019–2021